Human papillomavirus
Cervical cancer - is vaccination the way to go?
Series Name:
Nursing Update
Published by:
Democratic Nursing Organisation of South Africa
Cervical cancer is the second most prevalent cancer (second to breast cancer) to affect women in South Africa. The most common cancer to affect black women - 31 per cent of all cancers - it is also preventable and treatable. It is associated with the Human Papilloma Virus (HPV), of which the most prevalent strains are 16 and 18. Cervical cancer also appears to be an opportunistic infection among those living with HIV as it links to a weakened immune system. In South Africa a woman's risk of developing cervical cancer is one in 26. Each year 6 700 women develop cervical cancer while 3 700 die from the disease annually in South Africa.
Cancer risk soars in HIV-positive people
People with HIV have a much higher risk for many cancers, including anal cancer, but a lower risk for prostate cancer, researchers said on Tuesday. Some types of cancers like Kaposi's sarcoma and non-Hodgkin lymphoma have long been associated with people infected by the virus that causes AIDS.
Condoms Protect Against HPV and Are a Vital Complement to HPV Vaccine
RESEARCH TRIANGLE PARK, NC - A newly published study in the June 22, 2006 issue of the New England Journal of Medicine shows that use of condoms helps protect against human papillomavirus (HPV) infection, further substantiating condoms' usefulness in preventing most sexually transmitted infections, say two reproductive health experts at Family Health International (FHI) in an accompanying commentary.
Top level push to tackle priorities in sexual and reproductive health
20 JUNE 2006 GENEVA -- Leaders of the World Health Organization (WHO) and UNFPA, the United Nations Population Fund, are coordinating action to reverse the global trend of deteriorating levels of sexual and reproductive health and reduce the adverse impact on mothers, babies and young people.
Large, Randomized Study Confirms HPV Testing Is More Sensitive Than Both Conventional and Liquid-Based Pap Test
A study of more than 33,000 women published in the June issue of the Journal of the National Cancer Institute found that testing for high-risk types of the human papillomavirus (HPV) is a significantly more sensitive tool for cervical cancer screening than either conventional or liquid-based cytology (Pap testing), announced Digene Corp. (NASDAQ: DIGE).
FDA Approves Vaccine That Should Prevent Most Cervical Cancers
In what officials called a major public health breakthrough, the Food and Drug Administration yesterday approved the first vaccine developed to protect women against cervical cancer.
Swaziland: Major breakthrough in cervical cancer
A breakthrough might have been achieved with the recent acquisition of a vaccine for cervical cancer in women.
Cancer vaccine approval urged
The Medicines Control Council has been urged to fast-track approval of Gardasil, the first vaccine against cervical cancer.
The appeal came from the head of the South African subsidiary of Merck, the pharmaceutical company which late last year announced research results that pointed to the astonishing efficacy of the vaccine.
Studies examine ways to prevent cervical cancer with few resources
CHICAGO (AP) Low-income American women and women in developing countries who are tested for cervical cancer could benefit from faster, more aggressive treatment, two studies suggest.
New screen-and-treat methods for cervical cancer significantly reduce cancer precursor lesions
Columbia-led study of nearly 7,000 women overcomes traditional barriers to more expensive, cumbersome pap tests for highly preventable & treatable cancer.



